GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » Gross-Profit-to-Asset %

Cocrystal Pharma (STU:8CC) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cocrystal Pharma's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Cocrystal Pharma's average Total Assets over the quarter that ended in Dec. 2024 was €13.74 Mil. Therefore, Cocrystal Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.


Cocrystal Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Cocrystal Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Gross-Profit-to-Asset % Chart

Cocrystal Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 - - - -

Cocrystal Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cocrystal Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Cocrystal Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Gross-Profit-to-Asset % falls into.


;
;

Cocrystal Pharma Gross-Profit-to-Asset % Calculation

Cocrystal Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (28.665+12.85)/ 2 )
=0/20.7575
=0.00 %

Cocrystal Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (14.626+12.85)/ 2 )
=0/13.738
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Cocrystal Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma Headlines

No Headlines